Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

INTRODUCTION: Tyrosine kinase inhibitors (TKI) are medications of interest in the treatment of Systemic Sclerosis (SSc) because of their ability to inhibit pathways involved in fibrosis. In this open-label pilot trial, our objectives were to assess the safety, efficacy, and molecular change associat...

全面介紹

Na minha lista:
書目詳細資料
發表在:Arthritis Res Ther
Main Authors: Gordon, Jessica K., Martyanov, Viktor, Magro, Cynthia, Wildman, Horatio F., Wood, Tammara A., Huang, Wei-Ti, Crow, Mary K., Whitfield, Michael L., Spiera, Robert F.
格式: Artigo
語言:Inglês
出版: BioMed Central 2015
主題:
Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4538758/
https://ncbi.nlm.nih.gov/pubmed/26283632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-015-0721-3
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍